A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the pharmacodynamics (PD), pharmacokinetics (PK),
safety, and tolerability of multiple doses of RDEA3170 administered in combination with
febuxostat compared to RDEA3170 administered alone and febuxostat administered alone in
Japanese adult male subjects with gout or asymptomatic hyperuricemia.